EU Allows ‘Freezing’ & ‘Rolling Back’ Of Regulatory Timelines Due To COVID-19
Executive Summary
Guidance is now available to help drug companies that use the EU mutual recognition and decentralized procedures to handle regulatory processes during the COVID-19 crisis.